Literature DB >> 1992951

Drug treatment of Alzheimer's disease.

J K Cooper1.   

Abstract

Drugs may be part of the treatment for Alzheimer's disease. Drug treatment can be divided into two categories: treatment to improve cognitive function and treatment to improve abnormal behaviors. There are at least 16 new drugs undergoing evaluation that may improve cognitive function. Some of these drugs are intended to augment acetylcholine neurotransmitter function. Others are nootropics that affect neuron metabolism with little effect elsewhere. A third major category is drugs that affect brain vasculature. A miscellaneous group includes drugs aimed at modifying other defects found in Alzheimer's disease. Drugs to affect behavior have been available for some time. These include neuroleptics, anxiolytics, and antirage drugs. Use of all these drugs has been controversial. Recent federal legislation and guidelines affect their use in nursing homes. Specific indications for neuroleptics are psychotic features and agitation. Dosage for patients with dementia is different than for other psychotic patients. There is no consensus on the use of other psychoactive medications.

Entities:  

Mesh:

Year:  1991        PMID: 1992951

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  4 in total

Review 1.  The role of plant-derived drugs and herbal medicines in healthcare.

Authors:  P A De Smet
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

Review 2.  Drug treatment of Alzheimer's disease. Effects on caregiver burden and patient quality of life.

Authors:  L Hollister; N Gruber
Journal:  Drugs Aging       Date:  1996-01       Impact factor: 3.923

3.  Beta-adrenoceptor density and subtype distribution in cerebellum and hippocampus from patients with Alzheimer's disease.

Authors:  B Lemmer; L Langer; T Ohm; J Bohl
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-02       Impact factor: 3.000

4.  Inappropriate prescribing in hospitalised Australian elderly as determined by the STOPP criteria.

Authors:  Mohd Shahezwan Abd Wahab; Karin Nyfort-Hansen; Stefan R Kowalski
Journal:  Int J Clin Pharm       Date:  2012-08-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.